Macular edema secondary to branch retinal vein occlusion (BRVO-ME)
Conditions
Interventions
Experimental group:Intravitreal injection of Faricimab
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Signed informed consent; 2. Age >=18 years old at the time of signing the informed consent form; 3. Male and female patients who have been diagnosed with macular edema secondary to branch retinal vein occlusion (including non-ischemic BRVO and ischemic BRVO); 4. Patients who decide to receive treatment with faricimab and are not related to other studies.
Exclusion criteria
Exclusion criteria: 1. When eligibility is reconfirmed, the patient is not treated with faricimab; 2. Patients who cannot provide OCTA valid data within 2 weeks before receiving the first faricimab injection; 3. The study eye has received any previous faricimab or intravitreal injection of anti-VEGF drugs (including ranibizumab, aflibercept, conbercept, etc.) or intraocular long-acting corticosteroid therapy; 4. The study eye has received any focal or grille-like laser photocoagulation (within 1000um of the fovea) or any PRP treatment in the past; 5. Patients participating in other ophthalmic clinical trials within 28 days before admission; 6. Other situations that the investigator considers unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sight;Multifocal Electroretinogram, mfERG;Vascular density in DCP;The density of blood vessels in the SCP;Full - Area Outer Retina, FAOR;Full - Area Central Choroid, FACC;Non - Flow Area, NFA;Foveal Avascular Zone, FAZ;Sub - Retinal Fluid, SRF;Central Sub - foveal Thickness, CST;Intraretinal Fluid, IRF; | — |
Countries
China
Contacts
Public ContactDanning Liu
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed